Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli

International Journal of Pharmaceutics

Volumn 386, Issue 1-2, 2010, Pages 156-164

  Wang, Yin Jue ^a,b   Liu, Yong Dong ^a   Chen, Jing ^a,b   Hao, Su Juan ^c   Hu, Tao ^a   Ma, Guang Hui ^a   Su, Zhi Guo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Half life; Non glycosylated; PEGylation; Purification; Recombinant erythropoietin; Refolding

Indexed keywords

CARBONIC ACID; MACROGOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SUGAR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; ION EXCHANGE CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; RAT; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CATION EXCHANGE RESINS; CHO CELLS; CHROMATOGRAPHY, ION EXCHANGE; CRICETINAE; CRICETULUS; ERYTHROPOIETIN, RECOMBINANT; ESCHERICHIA COLI; FEASIBILITY STUDIES; GLYCOSYLATION; HALF-LIFE; HEMATINICS; HUMANS; INCLUSION BODIES; INJECTIONS, SUBCUTANEOUS; MALE; POLYETHYLENE GLYCOLS; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STABILITY; RATS; RATS, SPRAGUE-DAWLEY; SUCCINIMIDES; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 74149085504     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.11.016     Document Type: Article

References (30)

1. Boissel J.P., Lee W.R., Presnell S.R., Cohen F.E., and Bunn H.F. Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J. Biol. Chem. 268 (1993) 15983-15993
2. Bradford M.M., Mcrorie R.A., and Williams W.L. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
3. Cheetham J.C., Smith D.M., Aoki K.H., Stevenson J.L., Hoeffel T.J., Syed R.S., Egrie J., and Harvey T.S. NMR structure of human erythropoietin and a comparison to its receptor bound form. Nat. Struct. Biol. 5 (1998) 861-866
4. Davis J.M., Arakawa T., Strickland T.W., and Yphantis D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26 (1987) 2633-2638
5. De Bernardez Clark E., Hevehan D., Szela S., and Reddy J.M. Oxidative renaturation of hen egg-white lysozyme: folding vs aggregation. Biotechnol. Prog. 14 (1998) 47-54
6. Dordal M.S., Wang F.F., and Goldwasse E. The role of carbohydrate in erythropoietin action. Endocrinology 116 (1985) 2293-2299
7. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31 (2003) 290-299
8. Elliott S., Lorenzini T., Chang D., Barzilay J., and Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood 89 (1997) 493-502
9. Higuchi M., Oh-eda M., Kuboniwa H., Tomonoh K., Shimonaka Y., and Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J. Biol. Chem. 267 (1992) 7703-7709
10. Irani N., Beccaria A.J., and Wagner R. Expression of recombinant cytoplasmic yeast pyruvate carboxylase for the improvement of the production of human erythropoietin by recombinant BHK-21 cells. J. Biotechnol. 93 (2002) 269-282
11. Komatsu N., Nakauchi H., Miwa A., Ishihara T., Eguchi M., Moroi M., Okada M., Sato Y., Wada H., Yawata Y., Suda T., and Miura Y. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 51 (1991) 341-348
12. Krantz S.B. Erythropoietin. Blood 77 (1991) 419-434
13. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
14. Markham A., and Bryson H.M. Epoetin alpha. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49 (1995) 232-254
15. Mire-sluis A.R., and Thorpe R. Laboratory protocols for the quantitation of cytokines by bioassay using cytokine responsive cell lines. J. Immunol. Methods 211 (1998) 199-210
16. Narhi L.O., Arakawa T., Aoki K.H., Elmore R., Rohde M.F., Boone T., and Strickland T.W. The effect of carbohydrate on the structure and stability of erythropoietin. J. Biol. Chem. 266 (1991) 23022-23026
17. Narhi L.O., Arakawa T., Aoki K., Wen J., Elliott S., Boone T., and Cheetham J. Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng. 14 (2001) 135-140
18. Ouellette T., Destrau S., Ouellette T., Zhu J., Roach J.M., Coffman J.D., Hecht T., Lynch J.E., and Giardina S.L. Production and purification of refolded recombinant human IL-7 from inclusion bodies. Protein Expr. Purif. 30 (2003) 156-166
19. Park J.H., Kim C., Kim W.B., Kim Y.K., Lee S.Y., and Yang J.M. Efficiency of promoter and cell line in high-level expression of erythropoietin. Biotechnol. Appl. Biochem. 32 (2000) 167-172
20. Schriebl K., Trummer E., Lattenmayer C., Weik R., Kunert R., Müller D., Katinger H., and Vorauer-Uhl K. Biochemical characterization of rh-ngEpo-Fc fusion protein expressed in CHO cells. Protein Expr. Purif. 49 (2006) 265-275
21. Sharples E.J., Thiemermann C., and Yaqoob M.M. Novel applications of recombinant erythropoietin. Curr. Opin. Pharmacol. 6 (2006) 184-189
22. Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B., Zhan H., Osslund T.D., Chirino A.J., Zhang J., Finer-Moore J., Elliot S., Sitney K., Katz B.A., Matthews D.J., Wendoloski J.J., Egrie J., and Stroud R.M. Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature 395 (1998) 511-516
23. Tsumoto K., Ejima D., Kumagai I., and Arakawa T. Practical considerations in refolding proteins from inclusion bodies. Protein Expr. Purif. 28 (2003) 1-8
24. Veronese F.M., and Gianfranco P. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
25. Wang M.D., Yang M., Huzel N., and Butler M. Erythropoietin production from CHO cells grown by continuous culture in a fluidized-bed bioreactor. Biotechnol. Bioeng. 77 (2002) 194-203
26. Wasley L.C., Timony G., Murtha P., Stoudemire J., Dorner A.J., Caro J., Krieger M., and Kaufman R.J. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 77 (1991) 2624-2632
27. Wylie D.C., Voloch M., Lee S., Liu Y.H., Cannon-Carlson S., Cutler C., and Pramanik B. Carboxyalkylated histidine is a pH-dependent product of PEGylation with SC-PEG. Pharm. Res. 18 (2001) 1354-1360
28. Xie Y., and Wetlaufer D.B. Control of aggregation in protein refolding: the temperature-leap tactic. Protein Sci. 5 (1996) 517-523
29. Yamaguchi K., Akai K., Kawanishi G., Ueda M., Masida S., and Sasaki R. Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties. J. Biol. Chem. 266 (1991) 20434-20439
30. Zanette D., Soffientini A., Sottani C., and Sarubbi E. Evaluation of phenylboronate agarose for industrial-scale purification of erythropoietin from mammalian cell cultures. J. Biotechnol. 101 (2003) 275-287